anxi rovadicitinib tablets 5mg x 20 tablets per bottle

Description

Indication & Scope

AnXi® (Rovadicitinib) is a Class 1 innovative small-molecule kinase inhibitor developed by Chia Tai Tianqing Pharmaceutical Group for the first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) Rovadicitinib targets JAK and ROCK signaling pathways to reduce disease-related splenomegaly and improve myelofibrosis-associated symptoms.

Mechanism: Rovadicitinib selectively inhibits JAK1/2 and ROCK1/2 kinases. By blocking JAK-STAT signaling, it reduces inflammatory cytokine activity; inhibition of the ROCK-STAT3 pathway may reduce fibroblast activation associated with myelofibrosis.
Drug class: JAK/ROCK dual-target small-molecule kinase inhibitor.
Clinical use: First-line treatment of adult patients with intermediate-2 or high-risk PMF, PPV-MF, or PET-MF for disease-related splenomegaly and disease-associated symptoms.

Specification

Generic Name	Rovadicitinib Tablets
Brand Name	AnXi®
Ingredient	Rovadicitinib
Dosage Form	Tablet
Package	5mg x 30 tablets per bottle
Conditions Treated	Adult patients with intermediate-2 or high-risk PMF, PPV-MF, or PET-MF with disease-related splenomegaly or symptoms
Taboos	Hypersensitivity to rovadicitinib or any component of the product.
Place of origin	China
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store in a sealed container at room temperature
Manufacturer	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval number	H20260008
Date of Revision	2026
Shelf Life	24 months

How to use ?

Recommended Dose: 5 mg administered orally once daily according to the approved prescribing information.

Time: Administer once daily on an empty stomach.

Instructions for use: Swallow the tablet whole. Dose adjustments may be required based on blood cell counts and treatment tolerance. For patients experiencing severe thrombocytopenia or anemia, dose reduction to 5 mg every other day may be considered according to clinical evaluation.

Interaction: Strong CYP3A4 inhibitors may increase rovadicitinib exposure and require dose adjustment. Strong CYP3A4 inducers may reduce therapeutic exposure and should be avoided.

Side effects: Common adverse reactions include thrombocytopenia, anemia, neutropenia, nausea, headache, upper respiratory tract infection, and increased blood lipid levels.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

What is AnXi® (Rovadicitinib)?

AnXi® is a novel JAK/ROCK dual-target small-molecule inhibitor developed for the treatment of myelofibrosis.

What is it used for?

It is indicated for the first-line treatment of adults with intermediate-2 or high-risk PMF, PPV-MF, or PET-MF to reduce disease-related splenomegaly and symptoms.

How does it work?

It inhibits JAK1/2 and ROCK1/2 signaling pathways, reducing inflammatory signaling and fibroblast activation associated with myelofibrosis.

How should AnXi® be taken?

The recommended dose is 5 mg orally once daily on an empty stomach.